Developer of human and veterinary medicines specializing in identifying and developing biologically active molecules derived from the saliva of blood-feeding arthropod parasites, particularly ticks. The company has developed a platform technology which enables it to isolate biologicallyactive compounds and identify the genes which code for these molecules. The company has identified in excess of 100 biologically active molecules with therapeutic potential and six have progressed into development. The most advanced projects address asthma and allergic conjunctivitis. The company's lead product is in clinical Phase II in USA for conjunctivitis and rhinitis.